Aperiodic EEG features of cognition: a systematic review.

Rev NeurosciJun 4, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Klara Hemmerich, Alessia Santoni, Sara Stottmeier et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 45 studies on aperiodic EEG features and cognition in healthy adults aged 18-65. It found that steeper aperiodic spectra correlated with inhibitory control and conflict resolution, while flatter spectra were linked to sensory engagement and cognitive flexibility. The review highlights the importance of aperiodic activity in understanding cognitive processes.

Key findings

  • Steeper aperiodic spectra correlated with inhibitory control and conflict resolution.
  • Flatter aperiodic spectra were associated with sensory engagement and cognitive flexibility.
  • Aperiodic activity reflects both stable neural efficiency and flexible adaptability.

Why it matters

Understanding the relationship between aperiodic EEG features and cognitive functions can enhance insights into neural mechanisms underlying various cognitive processes, potentially informing future research and clinical assessments.

Source

PubMed · PMID 42240628

Published in Rev Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.